BIIB
Biogen Inc
NASDAQ: BIIB · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$194.38
+6.00% today
Updated 2026-04-29
Market cap
$28.53B
P/E ratio
20.92
P/S ratio
2.88x
EPS (TTM)
$9.29
Dividend yield
—
52W range
$115 – $202
Volume
1.1M
Biogen Inc (BIIB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
13.10%
Operating margin
19.60%
ROE
7.39%
ROA
6.14%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $2.68B | $217.51M | 89.77% | 16.40% | 8.11% |
| 2007 | $3.17B | $638.17M | 89.43% | 24.59% | 20.12% |
| 2008 | $4.10B | $783.17M | 90.19% | 29.62% | 19.11% |
| 2009 | $4.38B | $970.13M | 91.27% | 29.59% | 22.16% |
| 2010 | $4.72B | $1.01B | 91.51% | 26.48% | 21.31% |
| 2011 | $5.05B | $1.23B | 90.75% | 34.16% | 24.45% |
| 2012 | $5.51B | $1.38B | 90.11% | 33.34% | 25.02% |
| 2013 | $6.93B | $1.86B | 87.63% | 36.29% | 26.86% |
| 2014 | $9.70B | $2.93B | 87.93% | 40.94% | 30.25% |
| 2015 | $10.76B | $3.55B | 88.48% | 45.44% | 32.95% |
| 2016 | $11.45B | $3.70B | 87.48% | 45.00% | 32.34% |
| 2017 | $12.27B | $2.54B | 86.72% | 43.55% | 20.69% |
| 2018 | $13.45B | $4.43B | 86.50% | 43.77% | 32.93% |
| 2019 | $14.38B | $5.89B | 86.40% | 48.98% | 40.96% |
| 2020 | $13.44B | $4.00B | 86.57% | 34.16% | 29.76% |
| 2021 | $10.98B | $1.56B | 80.79% | 25.42% | 14.17% |
| 2022 | $10.17B | $3.05B | 77.61% | 28.40% | 29.95% |
| 2023 | $9.84B | $1.16B | 74.24% | 21.32% | 11.81% |
| 2024 | $9.68B | $1.63B | 76.12% | 25.74% | 16.87% |
| 2025 | $9.81B | $1.29B | 70.47% | 19.14% | 13.18% |